> Detailanzeige

Walker, Woolf T.; de Whalley, Philip; Andrews, Nick; Oeser, Clarissa; Casey, Michelle; Michaelis, Louise; Hoschler, Katja; Harrill, Caroline; Moulsdale, Phoebe; Thompson, Ben; Jones, Claire; Chalk, Jem; Kerridge, Simon; John, Tessa M.; Okike, Ifeanyichukwu; Ladhani, Shamez; Tomlinson, Richard; Heath, Paul T.; Miller, Elizabeth; Faust, Saul N.; Snape, Matthew D.; Finn, Adam; Pollard, Andrew J.

H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study
  • Beteiligte: Walker, Woolf T.; de Whalley, Philip; Andrews, Nick; Oeser, Clarissa; Casey, Michelle; Michaelis, Louise; Hoschler, Katja; Harrill, Caroline; Moulsdale, Phoebe; Thompson, Ben; Jones, Claire; Chalk, Jem; Kerridge, Simon; John, Tessa M.; Okike, Ifeanyichukwu; Ladhani, Shamez; Tomlinson, Richard; Heath, Paul T.; Miller, Elizabeth; Faust, Saul N.; Snape, Matthew D.; Finn, Adam; Pollard, Andrew J.
  • Erschienen: Oxford University Press, 2012
  • Erschienen in: Clinical Infectious Diseases, 54 (2012) 5, Seite 661-669
  • Sprache: Englisch
  • DOI: 10.1093/cid/cir905
  • ISSN: 1058-4838
  • Schlagwörter: ARTICLES AND COMMENTARIES
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <p>Background. We investigated antibody persistence in children 1 year after 2 doses of either an AS03 B -adjuvanted split-virion or nonadjuvanted whole-virion monovalent pandemic influenza vaccine and assessed the immunogenicity and reactogenicity of a subsequent dose of trivalent influenza vaccine (TIV). Methods. Children previously immunized at age 6 months to 12 years in the original study were invited to participate. After a blood sample was obtained to assess persistence of antibody against swine influenza A/H1N1(2009) pandemic influenza, children received 1 dose of 2010/2011 TIV, reactogenicity data were collected for 7 days, and another blood sample was obtained 21 days after vaccination. Results. Of 323 children recruited, 302 received TIV. Antibody persistence (defined as microneutralization [MN] titer ≥1:40) 1 year after initial vaccination was significantly higher in the AS03 B -adjuvanted compared with the whole-virion vaccine group, 100% (95% confidence interval [CI], 94.1%—100%) vs 32.4% (95% CI, 21.5%—44.8%) in children immunized &lt;3 years old and 96.9% (95% CI, 91.3%—99.4%) vs 65.9% (95% CI, 55.3%—75.5%) in those 3—12 years old at immunization, respectively (P &lt; .001 for both groups). All children receiving TIV had post-vaccination MN titers ≥1:40. Although TIV was well tolerated in all groups, reactogenicity in children &lt;5 years old was slightly greater in those who originally received AS03 B -adjuvanted vaccine. Conclusions. This study provides serological evidence that 2 doses of AS03 B -adjuvanted pandemic influenza vaccine may be sufficient to maintain protection across 2 influenza seasons. Administration of TIV to children who previously received 2 doses of either pandemic influenza vaccine is safe and is immunogenic for the H1N1 strain.</p>
  • Zugangsstatus: Freier Zugang